Don’t miss out! Join our webinar tomorrow as speakers from PharmAla Biotech and Clerkenwell Health discuss the work we’ve done together, optimizing trial design/clinical development and the current state of the market. bit.ly/3WohnfJ #psychedelics #webinar

We are less than an hour away from our webinar with Clerkenwell Health, register below to join the conversation! bit.ly/3WohnfJ #webinar #psychedelicswebinar #psychedelics #mentalhealth #clinicaltrials

Really interesting piece of research being conducted by Haley Maria Dourron

JOB ALERT! We're looking for a textile dyeing chemist to perfect our innovative direct dyeing process for natural bio-based colours. Apply now! linkedin.com/jobs/view/3654…

National coverage today of new psilocybin cost-effectiveness report co-authored by Clerkenwell Health's Dr Henry Fisher and Clare Knight with Greenwich University and Drug Science.

We are recruiting for a study on 'the many faces of psychedelic transformations': positive, negative and mixed significant changes. Please share to contribute to our understanding of the different outcomes that follow psychedelic experiences bit.ly/transformexe

Check out these highlights from our discussion led by Clerkenwell Health at PSYCH Symposium: London 2023. Our CEO, Nick Kadysh shares his thoughts on the importance of collaboration in this sector. Read more: bit.ly/3Oy4HRj #mdma #mdxx #psychedelics #clinicaltrails

I’m excited about this - a frank, thoughtful, and participatory discussion of interdisciplinarity in psychedelic research with Neşe Devenot, PhD 🍉 (@NeseLSD.bsky.social) and Emily Bloesch!

Nice to see our Clerkenwell Health rapid response to the recent reanalysis of the STAR*D trial results published in the BMJ_Open - suggesting that new treatments for depression have a place sooner than as a last resort in treatment resistant populations bmjopen.bmj.com/content/13/7/e…

Recruitment announcement:- Come & join me on The Loop Board of Trustees! The Loop CIO is expanding its Board ahead of an exciting new phase of expansion of #harmreduction services coming very soon. If you know a suitable competent & committed accountant please RT to them. 🙏🏻

One of those amazing people full of the most incredible stories that seems to always have been at the right place at the right time in history. He'll be missed by many!

Quite the adventure...

Please RT: We’re running a study looking at people’s experience of ketamine addiction treatment - heavy ketamine users current and past welcome bit.ly/ket-survey

With Chris Timmermann and Centre for Psychedelic Research we just launched a 🆒🆕 study to understand the practices used in underground #psychedelic therapy and how they differ from what we do in clinical trials. Please RT, forward to relevant ppl in your network🙏 More info: tinyurl.com/yey7ptmm

Have you ever had an underwhelming psilocybin experience? Liverpool John Moores University wants to interview you.

Such sad news - harm reduction pioneer and source of huge amounts of knowledge. RIP Dr Nuke

Really delighted to have joined the teaching faculty of Clerkenwell Health for their "Psychedelic Practitioner Foundation Programme". Follow this link to find out more (via the FAQ) and to sign up for the Foundation Programme. training.clerkenwellhealth.com/link/GV5BIl?ur…

This is one of the 2 big lessons for me: listen and even amplify criticism - medical scientists can never forget that it is all about the patients and the patients are often vulnerable. Engaging with criticism is the only honest and ethical way to do psychiatric science.

No. That’s not how this works. Any serious company seeking fda approval is going to look at how MAPS conducted itself, and then do better, or suffer the same fate

We are running a survey on post-psychedelic trip difficulties and what helped to cope with which specific difficulty, so if you have had extended challenging psychedelic experiences please do this 15min survey... all respondents get a copy of Jules' book Breaking Open